NIH Asthma Guide Concurs With FDA In Supporting LABAs For Adjunctive Use
Executive Summary
Sales of combination inhaled corticosteroid/long-acting beta2-agonists may receive a boost from NIH guidelines endorsing their use as adjunctive therapy in certain asthma patients
You may also be interested in...
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
FDA To Conduct Pediatric Safety Analysis for Serevent, Other LABAs
FDA will complete a risk/benefit analysis for pediatric use of GlaxoSmithKline's Serevent (salmeterol) as soon as possible, Pediatric Therapeutics Director Dianne Murphy assured the agency's Pediatrics Advisory Committee Nov. 28
Vaccines And Advair Keep GSK’s Earnings Steady Despite Avandia Losses
Despite losses from generic competition and falling Avandia sales, strong performances from GlaxoSmithKline's vaccines business and asthma therapy Advair kept its third quarter earnings fairly consistent with the year-ago period